Gilead Reports Updated Results of Descovy in P-III DISCOVER Study for Pre-Exposure Prophylaxis of HIV

Shots:

• The P-III DISCOVER study involves assessing of Descovy (emtricitabine, 200 mg/tenofovir alafenamide, 25 mg, qd) vs Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in adult male and transgender female with HIV PrEP
• The P-III DISCOVER study results: met its 1EPs of non-inferiority, reduction in time to achieve EC90 of tenofovir diphosphate (TFV-DP) in PBMCs, @4wks. TFV-DP level (98% vs 68%). Additionally, pharmacokinetic data showed Descovy maintains TFV-DP conc. level for a longer time than Truvada
• Descovy is a dual regimen therapy indicated in combination with other ARV for HIV-1 infections in patients weighing at least 35 kg

Click here to read full press release/ article | Ref: Gilead | Image:  STAT